Washington: Measuring the ratio of two enzymes in maternal plasma is an effective indicator for the early detection of fetal gender, a new study has suggested.
The new study describes findings that could lead to a non-invasive test that would let expecting mothers know the sex of their baby as early as the first trimester.
Researchers from South Korea discovered that various ratios of the enzymes DYS14 and GAPDH, which can be extracted from a pregnant mother’s blood, indicate if the baby will be a boy or a girl.
“Generally, early fetal gender determination has been performed by invasive procedures such as chorionic villus sampling or amniocentesis,” Hyun Mee Ryu, a researcher involved in the work from the Department of Obstetrics and Gynocology at Cheil General Hospital and Women’s Healthcare Center at the KwanDong University School of Medicine in Seoul, Korea, said.
“However, these invasive procedures still carry a one to two percent risk of miscarriage and cannot be performed until 11 weeks of gestation. Moreover, reliable determination of fetal gender using ultrasonography cannot be performed in the first trimester, because the development of external genitalia is not complete.
“Therefore, this can reduce the need for invasive procedures in pregnant women carrying an X-linked chromosomal abnormality and clarify inconclusive readings by ultrasound,” Ryu said.
To make this discovery, Ryu and colleagues collected maternal plasma from 203 women during their first trimester of pregnancy. The presence of circulating fetal DNA was confirmed by a quantitative methylation-specific polymerase chain reaction of U-PDE9A.
Multiplex real-time polymerase chain reaction was used to simultaneously quantify the amount of DYS14 and GAPDH in maternal plasma. The results were confirmed by phenotype at birth.
The study has been published in The FASEB Journal.